COHERUS ONCOLOGY INC

Coherus Biosciences, a Nasdaq‑listed biopharma firm, targets affordable biosimilars—investors eye its volatile stock, negative P/E, and growth potential in life‑saving therapies.

Coherus Oncology’s CCR8 antibody Tagmokitug shows a 15‑month survival boost, sparking a 12.4 % Nasdaq surge and signaling a possible shift from biosimilars to high‑margin oncology.